Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Dragnev

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|June 17, 2024
Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?Sai Yendamuri, Konstantin H Dragnev
Seminars in Oncology|December 10, 1999
The future beyond platinum for the treatment of advanced non-small cell lung cancerK H Dragnev, J R Rigas
The Oncologist|January 6, 2005
Emerging role of rexinoids in non-small cell lung cancer: focus on bexaroteneJames R Rigas, Konstantin H Dragnev
Chest|January 16, 2003
Lung cancer prevention: the guidelinesKonstantin H Dragnev, Diane Stover, Ethan Dmitrovsky, et al.
The Oncologist|October 21, 2000
The retinoids and cancer prevention mechanismsK H Dragnev, J R Rigas, E Dmitrovsky
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Cyclin D1 as a target for chemopreventionW Jeffrey Petty, Konstantin H Dragnev, Ethan Dmitrovsky
Cancer Biology & Therapy|September 26, 2003
Retinoid targets in cancer therapy and chemopreventionKonstantin H Dragnev, W Jeffrey Petty, Ethan Dmitrovsky
Biochemical Pharmacology|December 22, 1995
The chemopreventive agent diallyl sulfide. A structurally atypical phenobarbital-type inducerK H Dragnev, R W Nims, R A Lubet
Southern Medical Journal|April 1, 1998
Thymoma associated with syndrome of inappropriate antidiuretic hormone secretion and myasthenia gravisA C Donadio, K H Dragnev, G K Schwartz
Seminars in Oncology|July 15, 2005
Docetaxel in the treatment of esophageal cancerJames R Rigas, Konstantin H Dragnev, Jeffrey A Bubis
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Cancer Prevention Research (Philadelphia, Pa.)|June 17, 2024
Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?Sai Yendamuri, Konstantin H Dragnev
Seminars in Oncology|December 10, 1999
The future beyond platinum for the treatment of advanced non-small cell lung cancerK H Dragnev, J R Rigas
The Oncologist|January 6, 2005
Emerging role of rexinoids in non-small cell lung cancer: focus on bexaroteneJames R Rigas, Konstantin H Dragnev
Chest|January 16, 2003
Lung cancer prevention: the guidelinesKonstantin H Dragnev, Diane Stover, Ethan Dmitrovsky, et al.
The Oncologist|October 21, 2000
The retinoids and cancer prevention mechanismsK H Dragnev, J R Rigas, E Dmitrovsky
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Cyclin D1 as a target for chemopreventionW Jeffrey Petty, Konstantin H Dragnev, Ethan Dmitrovsky
Cancer Biology & Therapy|September 26, 2003
Retinoid targets in cancer therapy and chemopreventionKonstantin H Dragnev, W Jeffrey Petty, Ethan Dmitrovsky
Biochemical Pharmacology|December 22, 1995
The chemopreventive agent diallyl sulfide. A structurally atypical phenobarbital-type inducerK H Dragnev, R W Nims, R A Lubet
Southern Medical Journal|April 1, 1998
Thymoma associated with syndrome of inappropriate antidiuretic hormone secretion and myasthenia gravisA C Donadio, K H Dragnev, G K Schwartz
Seminars in Oncology|July 15, 2005
Docetaxel in the treatment of esophageal cancerJames R Rigas, Konstantin H Dragnev, Jeffrey A Bubis
Pageof 9